EMA Authorised: Caelyx pegylated liposomal (doxorubicin hydrochloride) — Baxter Holding B.V.

View source ↗

Summary

EMA authorised Caelyx pegylated liposomal doxorubicin hydrochloride for Kaposi's sarcoma, multiple myeloma, ovarian cancer, and breast cancer, with Baxter Holdi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Kaposi Sarcoma
• Multiple Myeloma
• Ovarian Cancer

Drugs mentioned

• Caelyx (liposomal doxorubicin)

Snippet

Status: Authorised. Therapeutic area: Sarcoma, Kaposi;Multiple Myeloma;Ovarian Neoplasms;Breast Neoplasms. MAH: Baxter Holding B.V.. Decision date: 24/04/2026